This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Pentacel
Pentacel is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b. Pentacel vaccine is approved for use as a four dose seriesin children 6 weeks through 4 years of age (prior to 5th birthday).
The diphtheria, tetanus, and pertussis components in Pentacelvaccine are based on the formulation in Daptacel-- Diphtheria and TetanusToxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine) -- which wasintroduced by sanofi pasteur in the U.S. in 2002.
In April 2012, Sanofi Pasteur temporarily imposed supply limitations for Pentacel and Daptacel vaccines in the U.S. due to a manufacturing delay that temporarily reduced the effective capacity to below the level needed to fully satisfy market demand in the U.S.
Additional information available to subscribers only: